Treatment of food allergy? This FDA-infinite drug helps children to eat peanuts, milk, and more!
A new clinical trial suggests that asthma drugs help children with drug omleizumbab (Xolair) to eat trigger foods safely. About 36 percent of the children treated for one year can consume full serving without serious reactions. Researchers say that this FDA-innovative drug may be a game-changer in the management of food allergies.
Treatment of food allergy? This FDA-infinite drug helps children to eat peanuts, milk, and more! (Image Credit: ISTOCK)
A new clinical trial has found that an injectable asthma can help children with severe food allergies to safely eat their trigger foods. The conclusions offered at the American Academy of Allergies, Asthma and Immunology meetings in San Diego offer fresh hope for families dealing with life-drew food allergies.
Promising test results
According to the results of Phase 2, 36 percent of children who had taken Omalizumab for one year were capable of eating full serving of foods from which they had earlier allergies. In contrast, only 19 percent of children who received a small course of medicine after oral immunotherapy got the same success.
Omalizumab works by targeting antibodies that cause allergic reactions, effectively neutralizing them. It has been in the market since 2003, mainly used to treat allergies asthma. However, the initial results of this study raised the US Food and Drug Administration (FDA) at one year of age to approve omalizumb for food allergies in both adults and children.
Understand study
The test of step 2 consisted of 117 children, whose average age was seven. Each child was allergic to peanuts and at least two other common allergies, such as milk, eggs, cashews, wheat, walnuts, or hazelnuts. By the week 44 of the study, they were given a testing service equal to 20 peanuts or half a cup of milk to evaluate their tolerance.
Children who received only oral immunotherapy were partially low success rates as more of them had to be left out due to adverse reactions. The study found that 88 percent of the children treated with omalizumab completed the test, while compared to only 51 percent of those undergoing oral immunotherapy. In addition, none of the Omlisub-credited children experienced serious allergic reactions, while more than 30 percent of people in the oral immunotherapy group.
A safe and more effective treatment
Dr. Robert Wood, Chief Investigator and Allergies, Director of Immunology, and Rumetology at Johns Hopkins Children’s Center emphasized the importance of these conclusions. “This is the first time we are able to compare these two remedies for many food allergies, and our study shows that Omlizumab was better than oral immunotherapy,” he said.
The study also included a phase 3 test, which tracked 60 children who developed tolerance through Omlizumbab Therapy. They were given one of the three options based on their reactions: continue eating food, undergoing oral immunotherapy, or avoiding food completely. Encouraged, more than 80 percent of children were assigned to actively eat their pre -allergenic foods.
Preliminary results showed that children were more successful in presenting milk, eggs and wheat in their diet (61 percent to 70 percent) than peanuts and tree nuts (38 percent to 56 percent). However, some children felt very serious of allergic reactions for the requirement of epinephreen shot. The study continues, the end result is expected to be the end of this year.
What does it mean to Johns Hopkins Children’s Center, a pediatrician, allergic victim Jennifer Dentor, explained the importance of conclusions: “Omlizumab is currently approved to reduce allergic reactions from casual exposure in the US. These results suggest that it may have extensive applications, but possible risks must be considered carefully. ,
Another senior researcher in the study, Dr. Sharon Chintrajah called the result a game changer. “This study is very encouraging because it shows that we have treatment options for our patients who are safe and not too much burden.”
Food allergy affects millions of children and adults worldwide, causing daily life to become stressful and even dangerous. This new research suggests that Omlizumab can provide a safe, more effective treatment option for children with many edible allergies. While more research is required, initial results are promising and can change the method of managing food allergies in the future.
The study was funded by Genentech, the manufacturer of Omalizumab. With all medical research, the findings presented at the conferences should be considered initial until a colleague is published in a reviewed magazine.
Now get the latest news with health and braking news and top headlines worldwide.
